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Low CSF 5-HIAA in Myoclonus Dystonia
Myoclonus Dystonia (MD; DYT11) is an early-onset hyperkinetic movement disorder with a prominent psychiatric phenotype caused by mutations in the E-sarcoglycan (SGCE) gene.
1 Although its precise function is unknown, multiple studies suggest E-sarcoglycan to be involved in monoamine metabolism and neurotransmission. We report 4 patients with SGCE-mutation-positive MD associated with low cerebrospinal fluid (CSF) levels of the serotonin metabolite, 5-hydroxyindoleacetic acid.
Patients and Methods
Cases were ascertained through (1) systematic searches of CSF Neurotransmitter Databases (National Hospital for Neurology and Neurosurgery, UK, and University Children's Hospital, Heidelberg, Germany (cases 1-3) and (2) collaboration with clinicians (case 4). SGCE mutation analysis was undertaken in diagnostic laboratories. Lumbar punctures were undertaken during investigation and CSF neurotransmitters analyzed using standardized protocols. CSF levels of the dopamine metabolite, homovanillic acid (HVA), serotonin metabolite, 5-HIAA (5-hydroxyindoleacetic acid), and pterin species were measured by high-performance liquid chromatography. Blood serotonin levels were measured for cases 1 to 3.
Results
Clinical and genetic characteristics are summarized in Figure 1A . In all cases, CSF 5-HIAA levels were below the lower limit of the normal reference range. All other CSF neurotransmitter metabolites were within normal expected values, except case 4 where HVA (88 nmol/L; age related reference range [ARRR]: 145-324 nmol/L) and tetrahydrobiopterin (6.8 nM; ARRR, 12-30 nM) were also reduced (Fig. 1A ).
Discussion
We report 4 patients with SGCE-mutation-positive MD associated with abnormal CSF 5-HIAA levels. To date, the CSF neurotransmitter profile of MD has not been delineated, because CSF neurotransmitter analysis is rarely undertaken in MD patients. Indeed, when MD is clinically suspected, early genetic testing and molecular confirmation of the diagnosis typically negates the need for further clinical investigations.
Isolated cerebral serotonin deficiency is increasingly recognized as a distinct clinical disorder (Fig. 1B) . 2, 3 A recent study showed 20% of childhood-onset movement disorders to be associated with reduced CSF 5-HIAA levels, 49% of these demonstrating an isolated CSF 5-HIAA reduction. 4 Serotonin has an important role during neuronal development, influencing cell differentiation and synaptogenesis, and mood and motor control in the mature brain. 5 Alcohol ingestion has also been observed to transiently increase serotonergic neurotransmission in animal models, potentially   FIG. 1 . Brain MRI at age 3. Axial T1-weighted (A), T2-weighted (B), and FLAIR (C) images showing selective, bilateral, and symmetrical mild hypointensity (A) and marked hyperintensity (B-C) of the caudate nuclei and putamina. The nuclei are slightly swollen. Axial diffusion-weighted imaging (diffusion weighted images b1000; D) and apparent diffusion coefficient maps (ADC; E) show restricted diffusion of the nuclei, representing cytotoxic edema. Brain MRI at age 5 was unchanged (data not shown).
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explaining its beneficial effects in MD. 6 Notably, 3 patients in our study had normal blood serotonin levels, suggesting that serotonin dyshomeostasis in MD may be tissue specific.
In contrast, the Sgce knockout mouse model found no reduction in striatal serotonin and 5-HIAA levels compared to controls, although elevated HVA levels were inversely correlated with 5-HIAA levels. 7 This discrepancy may be attributed to inherent differences between striatal tissue and CSF, or possible region specific changes in the rodent brain.
Reduced CSF HVA was observed in case 4, with values toward the lower end of the normal range in cases 1 to 3, a feature also observed in patients with primary neurotransmitter disorders (e.g., tyrosine hydroxylase deficiency; Fig.  1B) , depression, and alcoholism. 8, 9 Given that only 1 patient in our series had a definitively abnormal HVA level, its relevance in MD remains unclear.
Our report suggests a possible link between MD and impaired brain serotonin homeostasis. Underlying mechanisms potentially include impaired cerebral serotonin production, metabolism, or transport. Although not suggested as a routine investigation, it may be a useful future disease biomarker, which may guide biological models and provide a target for drug development. 
